


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231

SF 1404634 v1



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/042,039
Filing Date	October 25, 2001
First Named Inventor	Adams, Michael A., et. al.
Art Unit	1616
Examiner Name	PAK
Attorney Docket Number	10692V-000521US

RECEIVED
JAN 07 2003
TECH CENTER 160019001

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JP	CA	BRIZEL et al., "Tumor Hypoxia Adversely Affects the Prognosis of Carcinoma of the Head and Neck", <i>Int. J. Radiation Oncology Biol. Phys.</i> 1997 38(2):285-289	
	CB	BRIZEL et al., "Tumor Oxygenation Predicts for the Likelihood of Distant Metastases in Human Soft Tissue Sarcoma", <i>Cancer Research</i> 1996 56:941-943	
	CC	HARRIS et al., "Breast cancer angiogenesis-new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting", <i>Breast Cancer Research and Treatment</i> 1996 38:97-108	
	CD	HÖCKEL et al., "Association between Tumor Hypoxia and Malignant Progression in Advanced Cancer of the Uterine Cervix", <i>Cancer Research</i> 1998 58:4509-4515	
	CE	KONG et al., "Nitric oxide reduces tumor cell adhesion to isolated rat postcapillary venules", <i>Clin. Exp. Metastasis</i> 1996 14:335-343	
	CF	MITCHELL et al., "Radiation sensitisation by nitric oxide releasing agents", <i>British Journal of Cancer</i> 1996 74:(Suppl. XXVII) S181-S184	
	CG	MITCHELL et al., "Hypoxic mammalian cell radiosensitization by nitric oxide", <i>Cancer Research</i> 1993 53(24) 5845-5848 (ABSTRACT ONLY)	
	CH	MITCHELL et al., "Hypoxic Mammalian Cell Radiosensitization by Nitric Oxide", <i>Cancer Research</i> 1993 53:5845-5848	
	CI	PIPILI-SYNETOS et al., "Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate", <i>British Journal of Pharmacology</i> 1995 116:1829-1834	
	CJ	TEICHER B.A., "Hypoxia and drug resistance", <i>Cancer and Metastasis Reviews</i> 1994 13:139-168	
	CK	TRIKHA et al., "Nitroglycerin: a NO donor inhibits TPA-mediated tumor promotion in murine skin", <i>Carcinogenesis</i> 2001 22(8):1207-1211	
	CL	WINK et al., "Chemical biology of nitric oxide: insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide", <i>Free Radic Biol Med</i> 1998 25(4-5):434-456 (ABSTRACT ONLY)	
	CM	WINK et al., "Nitric Oxide and Some Nitric Oxide Donor Compounds Enhance the Cytotoxicity of Cisplatin", <i>Nitric Oxide: Biology and Chemistry</i> 1997 1(1):88-94	
	CN	XIE et al., "Therapy of cancer metastasis by activation of the inducible nitric oxide synthase", <i>Cancer and Metastasis Reviews</i> 1998 17:55-75	

Examiner
Signature

Date
Considered

6/14/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1404634 v1



Under the Paperwork Reduction Project

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sheet	3	of	3
-------	---	----	---

Application Number	10/042,039
Filing Date	October 25, 2001
First Named Inventor	Adams, Michael A., et. al.
Art Unit	1616
Examiner Name	PAK
Attorney Docket Number	10692V-000521US

TECH CENTER 1809/2900

RECEIVED
JAN 07 2003


[illegible]

[Handwritten signature]


6/14/05

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

SF 1404634 v1




Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/042,039	
			Filing Date	October 25, 2001	
			First Named Inventor	Adams, Michael A.	
			Art Unit	1616	
			Examiner Name	To Be Assigned PAK	
Sheet	1	of	3	Attorney Docket Number	10692V-000521US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	1.	5,434,256	07-18-1995	Khokhar et al.	
	2.	5,849,790	12-15-1998	Palmer et al.	
	3.	6,057,367	05-02-2000	Stamler et al.	
	4.	6,103,275	08-15-2000	Seitz et al.	
	5.	6,153,186	11-28-2000	Stamler et al.	
	6.	6,171,620 B1	01-09-2001	Piver et al.	
	7.	6,180,824 B1	01-30-2001	Stamler et al.	
	8.	6,203,789 B1	03-20-2001	Stamler et al.	
	9.	6,235,782 B1	05-22-2001	Pamukcu et al.	
	10.	6,270,779 B1	08-07-2001	Fitzhugh et al.	
	11.	2001-0038832 A1	11-08-2001	Bonavida et al.	
	12.	2002-0010146 A1	01-24-2002	Garvey et al.	
	13.	2003-0092637 A1	05-15-2003	Magnusson et al.	
	14.	2003-0215528 A1	11-20-2003	Graham et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
D	15.	DE	19732323	C2	08-19-1999	Dunzendorfer	Abstract only	<input type="checkbox"/>
	16.	WO	96/30336		10-03-1996	Latvian Inst.		<input type="checkbox"/>
	17.	WO	98/13358		04-02-1998	Saavedra et al.		<input type="checkbox"/>
	18.	WO	99/03462		01-28-1999	Brigham & Young		<input type="checkbox"/>
	19.	WO	99/33823		07-08-1999	Towart		<input type="checkbox"/>
	20.	WO	99/57306		11-11-1999	Adams et al.		<input type="checkbox"/>
	21.	WO	00/51597		09-08-2000	Ouellet et al.		<input type="checkbox"/>
	22.	WO	01/54771	A2	08-02-2001	Black et al.		<input type="checkbox"/>
	23.	WO	01/70199		09-27-2001	Zhao et al.		<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature		Date Considered	6/14/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.




Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/042,039		
		Filing Date	October 25, 2001		
		First Named Inventor	Adams, Michael A.		
		Art Unit	1616		
		Examiner Name	To Be Assigned PAK		
Sheet	2	of	3	Attorney Docket Number	10692V-000521US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JP	24.	CARDUCCI et al., "Effect of endothelin-a receptor blockage with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase ii, placebo-controlled trial" J. Clin. Oncol. 21(94):679-689 (2003)	
	25.	CHANG-DUK JUN et al., "High-dose nitric oxide induces apoptosis in HL-60 human myeloid leukemia cells"; Exper. Molec. Med. 23(2):101-108 (1996)	
	26.	CHEN et al., "Identification of the enzymatic mechanism of nitroglycerin bioactivation" PNAS 99(12):8306-8311 (2002)	
	27.	DOOKERAN, "Mechanisms of antitumor activity for sustained-release nitro-oxide donor, nitroprusside in ethiodol" Proceedings of the Annual Meeting of the American Association for Cancer Research 41(41):280 (2000)	
	28.	ELEY, K. et al., "The effects of pentoxifylline on the survival of human glioma cells with continuous and intermittent stereotactic radiosurgery irradiation" Int. J. Radiat. Oncol. Biol. Phys. 54(2):542-550 (2002)	
	29.	KIM et al., "Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia" Blood 92(7):2484-2494 (1998)	
	30.	MANNICK et al., "Fas-induced caspase denitrosylation" Science 284:651-654 (1999)	
	31.	MARSHALL et al., "Exhaled nitric oxide (NO), NO synthase activity, and regulation of nuclear factor (nf) - kb" Am. J. Respir. Cell Mol. Biol. 21:296-297 (1999)	
	32.	MARSHALL et al., "Nitrosative stress-induced apoptosis through inhibition of nf-kb" J. Biol. Chem. 277(37):34223-34228 (2002)	
	33.	PALLAVICINI, M. et al., "Effect of tumor blood flow manipulations on radiation response" Int. J. Radiat. Oncol. Biol. Phys. 9(9):1321-5 (1983) [Abstract]	
	34.	STIX, G., "Saying yes to NO" Scientific American p. 34 (November, 2001)	
	35.	SUMITANI et al., "Cytotoxic effect of sodium nitroprusside on cancer cells: involvement of apoptosis and suppression of C-MYC and C-MYB proto-oncogene expression"; Anticancer Res. Helenic Anticancer Institute 17(2A):865-872 (1997)	
	36.	SUN et al., "Cysteine-3635 is responsible for skeletal muscle ryanodine receptor modulation by NO" PNAS 98(20):11158-11162 (2001)	
	37.	UMANSKY, V. et al., "Activated endothelial cells induce apoptosis in lymphoma cells: role of nitric oxide" Int. J. Oncol. 10:465-471 (1997)	
	38.	UMANSKY, V. et al., "Nitric oxide-mediated apoptosis in human breast cancer cells requires changes in mitochondrial functions and is independent of CD95 (APO-1/Fas)" Int. J. Oncol. 16(1):109-117 (2000)	
	39.	USHMOROV, A. et al., "Nitric oxide-induced apoptosis in human leukemic lines requires mitochondrial lipid degradation and cytochrome C release" Blood 93(7):2342-2352 (1999)	

Examiner Signature		Date Considered	6/14/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/042,039		
		Filing Date	October 25, 2001		
		First Named Inventor	Adams, Michael A.		
		Art Unit	1616		
		Examiner Name	To Be Assigned PAK		
Sheet	3	of	3	Attorney Docket Number	10692V-000521US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	40.	YP et al., "Topical applications of caffeine or (-)-epigallocatechin gallate (egcg) inhibit carcinogenesis and selectively increase apoptosis in uvb-induced skin tumors in mice" PNAS USA 19:12455-12460 [Abstract]	

Examiner Signature		Date Considered	6/14/05
-----------------------	--	--------------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.